Comparison of topical nepafenac 0.1% and 0.3% on aqueous flare and macular thickness in patients with pseudoexfoliation following cataract surgery.

PURPOSE: To evaluate and compare the efficacy of topical nepafenac 0.1% administered three times daily versus nepafenac 0.3% administered once daily in patients with pseudoexfoliation syndrome (PEX) following routine cataract surgery.

METHODS

In this retrospective cohort study, patients with PEX undergoing routine cataract surgery were divided into two groups for analysis. Group 1 received nepafenac 0.1% three times daily, while Group 2 received nepafenac 0.3% once daily. In both groups, nepafenac was started 1 day before surgery and continued for 2 weeks postoperatively. Anterior chamber flare was quantified using laser flare photometry (LFP), and central macular thickness (CMT) was measured using optical coherence tomography. Measurements were taken preoperatively, at 1 week, and at 6 weeks postoperatively.

RESULTS

The study included 85 eyes from 85 patients, with 39 eyes in Group 1 and 46 eyes in Group 2. During the first postoperative week, Group 2 showed a significant reduction in LFP measurements ( P = 0.047) compared to Group 1. Notably, no significant difference was observed between the groups at the preoperative visit or at postoperative week 6. Comparisons of preoperative, 1-week, and 6-week postoperative CMT values also revealed no significant differences between the groups.

CONCLUSION

Nepafenac 0.3% used in routine cataract surgery in patients with PEX was shown to be at least as effective as nepafenac 0.1% in terms of aqueous flare and CMT. Aqueous flare values were more favorable with nepafenac 0.3% during the first week. In addition, the convenience of once-daily dosing may offer further advantages.